Intellia Therapeutics (NASDAQ:NTLA) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a research report released on Saturday morning.

Other equities analysts also recently issued research reports about the company. Evercore ISI set a $8.00 price target on Intellia Therapeutics and gave the stock an “in-line” rating in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Wednesday, October 8th. Citizens Jmp cut their price target on Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Robert W. Baird set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Thursday, October 30th. Finally, Wolfe Research reiterated a “peer perform” rating on shares of Intellia Therapeutics in a report on Wednesday, November 12th. Eleven investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $18.43.

Intellia Therapeutics Trading Down 3.2%

Shares of NTLA opened at $9.14 on Friday. The company’s fifty day simple moving average is $11.11 and its 200 day simple moving average is $12.70. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -2.14 and a beta of 2.13.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.10. The company had revenue of $13.78 million during the quarter, compared to the consensus estimate of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The company’s quarterly revenue was up 51.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.34) EPS. As a group, research analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Activity at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total value of $32,517.98. Following the transaction, the chief accounting officer directly owned 55,266 shares in the company, valued at approximately $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. CWM LLC increased its holdings in shares of Intellia Therapeutics by 4.7% during the third quarter. CWM LLC now owns 19,187 shares of the company’s stock worth $331,000 after purchasing an additional 856 shares during the period. Federated Hermes Inc. increased its stake in Intellia Therapeutics by 39.7% during the 3rd quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after acquiring an additional 927 shares during the period. Cyndeo Wealth Partners LLC increased its stake in Intellia Therapeutics by 9.3% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company’s stock worth $202,000 after acquiring an additional 995 shares during the period. Interchange Capital Partners LLC raised its holdings in Intellia Therapeutics by 9.7% in the 3rd quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock valued at $202,000 after acquiring an additional 1,030 shares in the last quarter. Finally, Benjamin Edwards Inc. lifted its position in shares of Intellia Therapeutics by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock valued at $591,000 after acquiring an additional 1,126 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.